

CURRICULUM VITAE

(1) **Name:** CHAN Leung Franky

(2) **Academic qualifications and training:**

BSc (The Chinese University of Hong Kong, 1981-1984)

PhD (The University of Hong Kong, 1984-1989)

Postdoctoral Fellow (McGill University, 1989-1992)

(3) **Previous appointments:**

Lecturer (1992-1995); Associate Professor (1995-2002); Professor 2 (2002-2008); Professor 1 (2008-2009), Department of Anatomy; Professor and Theme Chief, Cancer and Inflammation, School of Biomedical Sciences (2009-2016), The Chinese University of Hong Kong.

(4) **Present appointment (since 2017):**

Professor, Cancer Biology and Experimental Therapeutics, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong.

(5) **Research experience:**

Chan FL has been working on prostate gland and prostate cancer research for almost 30 years and published more than 130 original research papers in major ISI-indexed journals, including *Theranostics*, *Oncogene*, *Cancer Research*, *Journal of Pathology*, *PNAS*, *Journal of Clinical Endocrinology and Metabolism*, and *Endocrinology*. His research primarily focuses on hormonal carcinogenesis of prostate gland. His current studies in prostate cancer focus on: (1) functional roles of orphan nuclear receptors and their interplay with AR-dependent and -independent pathways in prostate cancer, (2) molecular pathways involved in castration-resistant prostate cancer and neuroendocrine prostate cancer, (3) growth regulation of prostate cancer stem cells, (4) epithelial-mesenchymal-transition and metastasis in prostate cancer and (5) immunotherapy of prostate cancer.

(6) **Relevant research works:**

Chan FL has been awarded with a total of (1) **22** external grants as PI, including 12 *RGC-Earmarked* or *RGC-GRF* Grants, 1 NFSC-RGC Joint Research Scheme, 3 *HMRF* grants, 2 *Innovative and Technology Funds*, 1 *PROCORE-France/Hong Kong RGC Joint Research Scheme* grant, 1 preclinical research grant (Janssen Oncology and Hematology), 2 Guangdong-Hong Kong joint research grants from Guangdong Province and (2) **5** external grants as co-I: including 3 *RGC-GRF* grants, 1 NFSC and 1 NFSC-RGC Joint Research Scheme since 1995.

(7) **Ten recent representative publications** (selected from a total of **133** peer-reviewed original research papers; *corresponding author):

1. Zhang X, Li H, Wang Y, Zhao H, Wang Z and **Chan FL***. Nuclear receptor NURR1 functions to promote stemness and epithelial-mesenchymal transition in prostate cancer via its targeting of Wnt/ β -catenin signaling pathway. *Cell Death & Disease* 2024;15:234.
2. Wang Y, Fan J, Chen T, Xu L, Liu P, Xiao L, Liu C, **Chan FL*** and Wu D*. A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer. *Frontiers in Endocrinology-Cancer Endocrinology* 2022;13:975623.

3. Gao W, Wang Y, Yu S, Wang Z, Ma T, Chan AM, Chiu PKF, Ng CF, Wu D and **Chan FL***. Endothelial nitric oxide synthase (eNOS)-NO signaling axis functions to promote the growth of prostate cancer stem-like cells. *Stem Cell Research & Therapy* 2022;13(1):188.
4. Zhou J, Wang Y, Wu D, Wang S, Chen Z, Xiang S and **Chan FL*** (2021) Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. *Oncogene* 2021;40(15): 2625-2634.
5. Xu Z, Ma T, Zhou J, Gao W, Li Y, Yu S, Wang Y and **Chan FL***. Nuclear receptor ERR α contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis. *Theranostics* 2020;10(9):4201-4216.
6. Wang Z, Li Y, Wu D, Yu S, Wang Y and **Chan FL***. Nuclear receptor HNF4 α performs a tumor suppressor function in prostate cancer via its induction of p21-driven cellular senescence. *Oncogene* 2020;39(7):1572-1589.
7. Wang Z, Li Y, Wang Y, Wu D, Lau AHY, Zhao P, Zou C, Dai Y and **Chan FL*** (2020) Targeting prostate cancer stem-like cells by an immunotherapeutic platform based on immunogenic peptide-sensitized dendritic cells-cytokine-induced killer cells. *Stem Cell Research & Therapy* 11:123
8. Gao W, Wu D, Wang Y, Wang Z, Zou C, Dai Y, Ng CF, Teoh JY, and **Chan FL*** (2018) Development of a novel and economical agar-based non-adherent three-dimensional culture method for enrichment of cancer stem-like cells. *Stem Cell Research & Therapy* 9: 243.
9. Xu Z, Wang Y, Xiao ZG, Zou C, Zhang X, Wang Z, Wu D, Yu S and **Chan FL***. Nuclear receptor ERR α and transcription factor ERG form a reciprocal loop in the regulation of *TMPRSS2:ERG* fusion gene in prostate cancer. *Oncogene* 2018;37:6259-6274.
10. Xiao L, Wang Y, Xu K, Hu H, Xu Z, Wu D, Wang Z, You W, Ng CF, Yu S and **Chan FL***. Nuclear receptor LRH-1 functions to promote castration-resistant growth of prostate cancer via its promotion of intratumoral androgen biosynthesis. *Cancer Research* 2018;78:2205-2218.

(8) Supervision and mentoring of postgraduate students:

- Number of postgraduate students trained since 1996: 8 MPhil students, 1 MSci, 22 PhD students
- Current postgraduate students being supervised (Total: 4)
 1. Ms. CHOPRA Ria, a Doctor of Philosophy student, 2021-2024
 2. Mr. LAW Chun Ho Alex, a Doctor of Philosophy student, 2021-2024
 3. Mr. LAM Hau Tak Daniel, a Doctor of Philosophy student, 2021-2025
 4. Ms. GAO Tiantian, a Doctor of Philosophy student, 2023-2026